Short Interest in Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Declines By 22.7%

Calliditas Therapeutics AB (publ) (NASDAQ:CALTGet Rating) was the target of a large drop in short interest in the month of July. As of July 15th, there was short interest totalling 7,500 shares, a drop of 22.7% from the June 30th total of 9,700 shares. Based on an average daily volume of 7,100 shares, the days-to-cover ratio is presently 1.1 days.

Hedge Funds Weigh In On Calliditas Therapeutics AB (publ)

An institutional investor recently bought a new position in Calliditas Therapeutics AB (publ) stock. Jane Street Group LLC acquired a new position in shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALTGet Rating) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 11,543 shares of the company’s stock, valued at approximately $221,000. 25.10% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on CALT. Pareto Securities began coverage on shares of Calliditas Therapeutics AB (publ) in a research report on Thursday, June 2nd. They issued a “buy” rating for the company. Kepler Capital Markets began coverage on shares of Calliditas Therapeutics AB (publ) in a research report on Thursday, June 16th. They issued a “buy” rating for the company.

Calliditas Therapeutics AB (publ) Price Performance

CALT opened at $20.45 on Wednesday. The company has a debt-to-equity ratio of 0.25, a current ratio of 5.37 and a quick ratio of 5.36. The company has a market capitalization of $544.58 million, a price-to-earnings ratio of -8.15 and a beta of 1.60. The firm’s fifty day moving average price is $18.18 and its two-hundred day moving average price is $18.31. Calliditas Therapeutics AB has a 1 year low of $12.55 and a 1 year high of $32.92.

Calliditas Therapeutics AB (publ) (NASDAQ:CALTGet Rating) last posted its quarterly earnings data on Wednesday, May 18th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.38). The business had revenue of $5.33 million for the quarter, compared to analysts’ expectations of $5.26 million. As a group, analysts anticipate that Calliditas Therapeutics AB will post -2.81 earnings per share for the current fiscal year.

About Calliditas Therapeutics AB (publ)

(Get Rating)

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.

See Also

Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.